Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes

Inclusion Criteria:

1. Male or female, age ≥ 18 years and ≤75 years old at the time of screening.
2. Subjects diagnosed with type 2 diabetes for at least 6 months (WHO, 1999)
3. Within 60 days before screening, subjects received stable treatment with onlymetformin ≥ 1500 mg/day (or maximum tolerated dose ≥ 1000 mg/day), or receivecombination metformin (dose ≥ 750 mg/day) and another OAD (alpha-glucosidaseinhibitors, sulfonylureas, glinides, SGLT-2i or thiazolidinedione), stable treatmentis defined as unchanged medication and daily doses;
4. At the time of screening, for those who have previously been treated with metforminalone, HbA1c ≥ 7.0% and ≤ 11.0%（local lab）; for those who have previously usedmetformin in combination with another OAD treatment, HbA1c ≥ 7.0% and ≤10.0%（locallab）;
5. BMI≥18.5kg/m2 and ≤35 kg/m2
6. Subjects voluntarily participate in this research, can communicate well withresearchers, are willing to maintain the same diet and exercise habits throughout thestudy, and sign an informed consent form (ICF) .
7. At baseline，HbAlc ≥ 7.0% and ≤ 11.0%（cental lab）

Exclusion Criteria:

1. Known or suspected hypersensitivity to any GLP-1RA or related products, or allergicconstitution
2. Treatment with GLP-1RA, DPP-4 inhibitor, or insulin in a period of 60 days beforescreening. An exception is short-term insulin therapy (≤7 days in total).
3. History of chronic or acute pancreatitis
4. Screening calcitonin value ≥ 50 ng/L (pg/mL)
5. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrineneoplasia syndrome type 2 (MEN 2)
6. Have a history of major cardiovascular and cerebrovascular diseases within 90 daysbefore screening.
7. Known proliferative retinopathy or maculopathy